Evidence map›Paper›PMID 33742793›Full record

ArticleCancer reports (Hoboken, N.J.)2021

COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran.

Soodabeh Shahidsales, Seyed Amir Aledavood, Mona Joudi, Fatemeh Molaie, Habibollah Esmaily, Seyed Alireza Javadinia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Observational
  14. The Effects of the COVID-19 Pandemic in Oncology Patient Management.International journal of environmental research and public health · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Soodabeh ShahidsalesCancer Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Amir AledavoodCancer Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
Mona JoudiCancer Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh MolaieStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0002-7267-9943
Habibollah EsmailyDepartment of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Alireza JavadiniaCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.ORCID 0000-0003-2467-837X
Mashhad University of Medical Sciences · IRSabzevar University of Medical Sciences · IR

Funding

Mashhad University of Medical Sciences 990087
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) pandemic imposes serious problems to health systems around the world and its rapid expansion makes it difficult to serve patients with certain health conditions such as cancer patients which might be at high risk for mortality if they are infected by the severe acute respiratory syndrome coronavirus 2.

aimTo compare the outcomes of cancer patients admitted due to COVID-19 and compare them with data of COVID-19 infected patients without a history of cancer.

methodsIn this case-controlled study, 93 healthy people and 92 patients with malignancy admitted for COVID-19 were enrolled. The clinical features and laboratory indicators were assessed at the presentation and both groups were followed-up for treatment options and outcomes prospectively and compared at the level of P ≤ .05.

resultsCOVID-19 related mortality rate in malignant patients was significantly higher than patients without malignancy (41.3% vs 17.2%, P = .0001). The risk of death increased significantly in patients with malignancy (OR = 8.4, P = .007) and mechanical ventilation (OR = 3.3, P = .034) independent of other variables. Fever (64.5% vs 43.5%, P = .004), chill (35.5% vs 14.1%, P = .001), malaise (49.5% and 30.4%, P = .008), dry cough (51.6% vs 26.1%, P = .0001), and vomiting (17.2% vs 5.4%, P = .012) were reported significantly lower in cancer patients.

conclusionThe results suggest that cancer patients who were infected by COVID-19 may present with atypical symptoms are at higher risk of mortality independent of the demographic data, comorbidities, and treatments.

Indexed as

Case-Control StudiesComorbidityCOVID-19FemaleFollow-Up StudiesHumansIranMaleMiddle AgedNeoplasmsRisk AssessmentRisk FactorsSARS-CoV-2Severity of Illness IndexCOVID-19malignancymortality

Identifiers

PMID33742793
PMCPMC8250318
OpenAlexW3139333824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.